Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate)

• Neodolpasse combines an NSAID and a muscle relaxant to address conditions involving pain, inflammation and spasm.
• Acute pain: provides rapid analgesia and reduces inflammatory mediators.
• Inflammation: diminishes prostaglandin synthesis to limit swelling.
• Muscle spasm: relaxes skeletal muscle tone through central anticholinergic action.

• Diclofenac sodium inhibits cyclo‑oxygenase‑1 and‑2 enzymes, lowering prostaglandin production and thereby reducing pain and inflammation. Orphenadrine citrate acts as a centrally acting anticholinergic muscle relaxant, blocking muscarinic receptors and modulating norepinephrine reuptake, which leads to decreased muscle hyperactivity and spasm.

Neodolpasse may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Gastrointestinal discomfort or dyspepsia.
• Headache or dizziness.
• Injection site pain or erythema.
• Transient elevation of liver enzymes.
• Mild hypotension.
• Nausea or vomiting.

Serious or Rare Side Effects

• Severe allergic reactions such as anaphylaxis.
• Hepatotoxicity with marked liver enzyme rise.
• Renal impairment or acute kidney injury.
• Gastrointestinal ulceration or bleeding.
• Cardiac events including myocardial infarction.
• Severe skin reactions like Stevens‑Johnson syndrome.

• Before using Neodolpasse, consider the following safety measures.
• Renal function: assess baseline kidney status, especially in patients with chronic disease.
• Hepatic health: monitor liver enzymes in patients with existing liver conditions.
• Cardiovascular risk: use cautiously in individuals with known heart disease or hypertension.
• Bleeding tendency: avoid in patients with active ulcers or coagulopathy.
• Pregnancy and lactation: safety not established; weigh benefits against potential risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neodolpasse can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased bleeding risk.
• Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal toxicity.
• Lithium: diclofenac may raise lithium serum levels.
• MAO inhibitors: potential for hypertensive crisis with orphenadrine.
• Cytochrome P450 inhibitors: may elevate diclofenac concentrations.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: possible reduction in renal function.
• Diuretics: may enhance nephrotoxic potential.
• Corticosteroids: additive risk of GI ulceration.
• SSRIs or SNRIs: increased bleeding tendency.
• Antihypertensives: orphenadrine may counteract blood pressure control.